In conclusion, we found that the expression of the CSC marker CD15 was higher in the ATA intermediate risk group than in the low risk group and that the expression of CSC markers is associated with more aggressive tumor characteristics and poor prognosis, thus providing a rationale to evaluate CSC markers in PTC. The gene discussed is FUT4; the disease is neoplasm.